Stocks and Investing
Stocks and Investing
Thu, October 28, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Michael Schmitz Maintained (BPMC) at Strong Buy with Increased Target to $122 on, Oct 28th, 2021
Michael Schmitz of Guggenheim, Maintained "Blueprint Medicines Corporation" (BPMC) at Strong Buy with Increased Target from $120 to $122 on, Oct 28th, 2021.
Michael has made no other calls on BPMC in the last 4 months.
There is 1 other peer that has a rating on BPMC. Out of the 1 peers that are also analyzing BPMC, all agrees with Michael's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $96 on, Friday, July 30th, 2021
Contributing Sources